Oncology

RareCan, a new company accelerating research into rare cancers, has appointed Dr Anita Cooper as Non-Executive Director. The appointment is said to strengthen the scientific and pharmaceutical experience of RareCan’s board in support of the company’s planned commercial growth. With over 30 years’ global business experience, Cooper has worked across diverse functions, skill levels and […]

A Mount Sinai study titled Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease describes how a novel therapeutic (108600) combats aggressive chemotherapy-resistant triple-negative breast cancer (TBNC). 108600 targets and inhibits breast cancer stem cells, a subpopulation of cells found within patient triple negative breast cancers that can promote […]

Ixaka and SomaLogic have created a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamers. Ixaka is […]

Mari Scheiffele is the General Manager for Oncology in the UK & Ireland at Novartis, responsible for launching innovative oncology therapies that can help to change the lives of people living with different types of cancer. She speaks to Lu Rahman about her passion for working with her teams to deliver innovative medicines to patients […]

National Institutes of Health scientists and their collaborators have identified an internal communication network in mammals that may regulate tissue repair and inflammation, providing new insights on how diseases such as obesity and inflammatory skin disorders develop. The new research is published in Cell. The billions of organisms living on body surfaces such as the […]

GlaxoSmithKline has announced New GSK, which will deliver step-change in growth and performance over next ten years, driven by a high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline. New GSK will keep a 20% stake in the consumer healthcare business. The Independent confirmed: “The unit will be listed on the London Stock Exchange as a separate […]

In the last decade, cancer immunotherapy has emerged as one the most promising treatments for the disease. In a recent pilot study, Professor Joachim Drevs and his co-authors; Joachim Ahlers, Eglys Gonzalez Marcano and Leona Kröhle describe how a new autologous vaccine developed in partnership with cancer clinic RGCC created a confirmed anti-tumour response in […]

Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer. This […]

Matwin has picked four companies that will now receive investment from the French oncology accelerator. This was during the MEET2WIN European Oncology Partnering Convention. Step Pharma was awarded ‘First-in-class therapeutic innovation’. The startup’s lead program (STP938) is based on a novel class of oral nucleotide synthesis inhibitors that target CTPS1 (cytidine triphosphate synthase 1) to […]

Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour response. The findings provide more […]